image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

SIGN UP NOW
Updates

Medica

June 2021

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • MGP
  • Price:
  • 160p
Medica has announced the acquisition of Pennsylvania-based RadMD, taking it into the exciting US$1bn global clinical trial imaging market, which is forecast to grow 5.7% CAGR to 2028. Whereas Medica focuses on time sensitive diagnostic reporting, RadMD reads images under strict regulatory protocols as part of multi-phase clinical trial studies. Operating through a network of 250 radiologists, RadMD provides imaging clinical research services including full management of all imaging aspects of clinical trials, expert image review and consulting services provided to pharma, biotech and contract research organisations. Earnings visibility is strong thanks to its US$40m order book and historic book to bill ratio for the following ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

Medica (June 2023)
Medica (December 2020)
Medica Group (September 2020)
Medica Group (May 2020)
Medica Group (September 2019)
Medica Group - Net debt eliminated (May 2019)
Medica Group (April 2019)
Medica - Fast growing provider of teleradiology services looks very cheap (November 2018)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X